biostudies-literatureCervero-Garcia PBlood Cancer UKvdag001https://www.ebi.ac.uk/biostudies/studies/S-EPMC12932952biostudies-literatureUnknown8(1)<h4>Background</h4>TAT-Cx43_266-283 is a novel Src inhibitor, which has shown noteworthy antitumor effects in preclinical models of glioblastoma. Because Src plays a pivotal role in several tumor types, including lung cancer brain metastasis derived from non-small cell lung cancer (NSCLC) cells, we investigated the effect of TAT-Cx43_266-283 in NSCLC-derived brain metastasis, a disease of unmet clinical need.<h4>Methods</h4>The effect of TAT-Cx43_266-283 was studied in Lewis Lung Carcinoma (LLC), LSZ4, A549, and H441 NSCLC cells. The non-adherent stem-like LLC cells (LLC-CSCs) were intracranially implanted in immunocompetent mice to study the effect of TAT-Cx43_266-283  <i>in vivo</i>. Phosphoproteomic analysis was employed to identify signaling pathNeuro-oncology advancesThe Src inhibitor peptide TAT-Cx43&lt;sub&gt;266-283&lt;/sub&gt; improves survival in an intracranial murine model of lung cancer brain metastasis.PMC1293295220008Hijazi MRodrigues-Teixeira TAlvarez-Vazquez AAlonso-Amador JJOllauri-Ibanez CMartin-Guerrero SMCutillas PRCasado PGarcia-Guerrero LShields TFlores-Hernandez RTalaveron RTabernero ARajeeve VCervero-Garcia PJimenez-Madrona EPaniagua-Sancho MJaraiz-Rodriguez MGonzalez-Sanchez RGarcia-Vicente LfalseThe Src inhibitor peptide TAT-Cx43&lt;sub&gt;266-283&lt;/sub&gt; improves survival in an intracranial murine model of lung cancer brain metastasis.<h4>Background</h4>TAT-Cx43_266-283 is a novel Src inhibitor, which has shown noteworthy antitumor effects in preclinical models of glioblastoma. Because Src plays a pivotal role in several tumor types, including lung cancer brain metastasis derived from non-small cell lung cancer (NSCLC) cells, we investigated the effect of TAT-Cx43_266-283 in NSCLC-derived brain metastasis, a disease of unmet clinical need.<h4>Methods</h4>The effect of TAT-Cx43_266-283 was studied in Lewis Lung Carcinoma (LLC), LSZ4, A549, and H441 NSCLC cells. The non-adherent stem-like LLC cells (LLC-CSCs) were intracranially implanted in immunocompetent mice to study the effect of TAT-Cx43_266-283  <i>in vivo</i>. Phosphoproteomic analysis was employed to identify signaling path2026-01-01T00:00:00Z2026 Jan-Dec2026-07-14T09:22:02.553Z2026-07-14T03:04:15.919ZS-EPMC129329524175675710.1093/noajnl/vdag001